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Summary
 
The pre-T cell receptor 
 
a
 
 (pT
 
a
 
) protein is a critical component of the pre-T cell receptor
complex in early thymocytes. The expression of the pT
 
a
 
 gene is one of the earliest markers of
the T cell lineage and occurs exclusively in pre-T cells. To investigate the molecular basis of
thymocyte-specific gene expression, we searched for the genomic elements regulating tran-
scription of the mouse pT
 
a
 
 gene. We now report that expression of the pT
 
a
 
 gene is primarily
controlled by an upstream genomic region, which can drive thymocyte-specific expression of a
marker gene in transgenic mice. Within this region, we have identified two specific DNase-
hypersensitive sites corresponding to a proximal promoter and an upstream transcriptional
enhancer. The pT
 
a
 
 enhancer appears to function preferentially in pre-T cell lines and binds
multiple nuclear factors, including YY1. The enhancer also contains two G-rich stretches ho-
mologous to a critical region of the thymocyte-specific 
 
lck
 
 proximal promoter. Here we show
that these sites bind a common nuclear factor and identify it as the zinc finger protein ZBP-89.
Our data establish a novel experimental model for thymocyte-specific gene expression and sug-
gest an important role for ZBP-89 in T cell development.
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T
 
he development of a diverse and functional lympho-
cyte repertoire is achieved through the precise regula-
tion of gene expression in various lymphoid lineages and at
different developmental stages (1). As a powerful approach
to the study of gene regulation in the immune system, ge-
nomic elements controlling the expression of lymphocyte-
specific genes have been identified and used to isolate tran-
scription factors involved in lymphocyte development (2).
The regulatory mechanisms underlying gene expression
during the specification of the T cell lineage and its subse-
quent effector differentiation are being rapidly uncovered.
Transcriptional regulation of many T cell–specific genes,
particularly the TCR genes (3), has been described in great
detail. Several transcription factors, including common
lymphoid factors such as PU.1 and Ikaros and T cell–spe-
cific factors, such as GATA3 and TCF1/LEF1, were found
to be critical for T cell development by gene targeting
techniques (4). In contrast, our understanding of stage-spe-
cific gene expression in T cell development is still limited.
Although several stage-specific regulatory elements such as
alternative 
 
lck
 
 promoters (5), a CD4 silencer (6, 7), and
CD8 enhancers (8–10) have been identified, their mode of
action is not fully understood. In particular, molecular
mechanisms that bring about gene expression specifically in
pre-T cells remain to be elucidated.
The pre-TCR-
 
a
 
 (pT
 
a
 
)
 
1
 
 protein pairs with a newly syn-
thesized TCR-
 
b
 
 chain to form the pre-TCR, which trans-
duces an obligatory survival signal to developing T cells at
the so-called “
 
b
 
 selection” checkpoint (11). As an essential
component of the pre-TCR, pT
 
a
 
 is critical for the effi-
cient generation of T cells with productive TCR-
 
b
 
 rear-
rangements, allelic exclusion at the TCR-
 
b
 
 locus, and lin-
eage commitment of 
 
a/b
 
 T cells (12). Consistent with its
function at the early stages of T cell development, the pT
 
a
 
gene is expressed in pre-T cells in the thymus and extrathy-
mic T cell maturation sites but not in mature thymocytes,
peripheral T cells, or other cell types (13, 14). Moreover,
pT
 
a
 
 appears to be one of the earliest molecular markers of
the T cell lineage, as its expression was detected in T cell
progenitors in the mouse bone marrow and fetal blood (14),
as well as in adult human blood (15). In view of its pre-T
cell–specific expression, the pT
 
a
 
 gene may provide an at-
tractive model system to study the transcriptional regulation
of early T cell development. To this end, we set out to char-
acterize regulatory regions within the mouse pT
 
a
 
 locus.
 
1
 
Abbreviations used in this paper:
 
 DHS, DNase-hypersensitive site; EMSA,
electrophoretic mobility shift assay; GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase; pT
 
a
 
, pre-TCR-
 
a
 
; UTR, untranslated region. 
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Materials and Methods
 
DNA Constructs.
 
Mouse pT
 
a
 
 cDNA probe was amplified
by reverse transcriptase (RT)-PCR as described (13) and used to
screen a 129/SvJ mouse bacterial artificial chromosome genomic
library (Genome Systems). A positive clone encompassing 
 
.
 
100
kb of pT
 
a
 
 locus was isolated and used for restriction mapping
with oligonucleotide probes and for subcloning into plasmid vec-
tors. The sequencing and mapping data were consistent with
those reported previously (16).
For reporter assays, a 5
 
9
 
 pT
 
a
 
 fragment spanning 1.2 kb up to
the PstI site within the known 5
 
9
 
 untranslated region (UTR) (16)
was subcloned into the HindIII site of the promoterless LacZ
(
 
Escherichia coli
 
 
 
b
 
-galactosidase) reporter vector p
 
b
 
gal-Basic (Clon-
tech). An 8-kb XhoI-BglII 5
 
9
 
 fragment was subcloned into
XhoI-BglII sites of this construct to create a 9-kb XhoI-PstI 5
 
9
 
pT
 
a
 
 fragment upstream of LacZ. Promoter and enhancer map-
ping were carried out by in-vector deletions of the above con-
structs or by subcloning of fragments upstream of the pT
 
a
 
 pro-
moter. The BstEII-MluNI enhancer fragment was subcloned into
pBluescript and sequenced using T3 and T7 primers. As hetero-
logous promoters, we used the CMV immediate early promoter
and the SV40 early promoter (p
 
b
 
gal-Promoter vector; Clontech)
subcloned upstream of LacZ in the p
 
b
 
gal-Basic vector. As con-
trol enhancers, we used 0.6-kb mouse CD3
 
d
 
 enhancer (reference
17; a gift of Dr. Cox Terhorst, Harvard Medical School) and
0.55-kb human CD2 enhancer fragment (18). To examine en-
hancer activity in various cell lines, 4.3-kb NheI-BglII and 0.35-kb
BstEII-NarI pT
 
a
 
 enhancer fragments were subcloned upstream
of the SV40 promoter in the p
 
b
 
gal-Promoter vector.
For deletion analysis of the pT
 
a
 
 enhancer, fragments were am-
plified by PCR using Pwo DNA polymerase (Roche Molecular
Biochemicals) and subcloned into the KpnI-BglII sites of the
p
 
b
 
gal-Promoter vector. Site-directed mutagenesis was performed
using the QuikChange kit (Stratagene). All of these constructs
were verified by sequencing using a primer within the SV40 pro-
moter.
 
Cells.
 
A panel of T cell lymphomas, either derived in this
laboratory from various knockout mouse strains or obtained from
the American Type Culture Collection, was screened for the ex-
pression of pT
 
a
 
 mRNA by Northern hybridization and RT-PCR
(data not shown). The pT
 
a
 
-positive lines included LR1 (
 
atm
 
2
 
/
 
2
 
rag-2
 
2
 
/
 
2
 
), 642 (
 
p53
 
2
 
/
 
2
 
), and 799 (
 
atm
 
2
 
/
 
2
 
p53
 
2
 
/
 
2
 
); the pT
 
a
 
-nega-
tive lines included LR2 (
 
atm
 
2
 
/
 
2
 
rag-2
 
2
 
/
 
2
 
), EL4, and BW5147.
Other cell lines included 1105, a B cell lymphoma from a c-myc–
transgenic animal; MEL, a mouse erythroleukemia line; and
NIH3T3 mouse fibroblasts. All lines were cultured in DMEM
with 10% FCS, 
 
l
 
-glutamine, and 2-ME.
 
DNase Hypersensitivity Assay.
 
Cells were harvested and lysed
in reticulocyte standard buffer (10 mM Tris/HCl, pH 7.4, 10 mM
NaCl, 5 mM MgCl
 
2
 
) with 0.5% NP-40. Nuclei were washed and
resuspended in reticulocyte standard buffer and treated with two-
fold dilutions of DNase I (Roche Molecular Biochemicals) for 5
min at room temperature. The reaction was stopped with a buffer
containing 1% SDS, 50 mM EDTA, and proteinase K, and DNA
was extracted, digested with appropriate enzymes, and analyzed
by Southern hybridization. For the comparison between different
cell lines, the amount of DNase was calibrated for each line and
three concentrations were chosen: (i) the minimal DNase con-
centration producing a visible downshift of DNA fragments after
restriction digest, (ii) a twofold lower concentration, and (iii) no
DNase.
The following genomic probes were used: a 0.46-kb PstI-
NcoI fragment encompassing pT
 
a
 
 exon 2 (probe 1); a 0.5-kb
 
XhoI-HpaI fragment 10 kb 5
 
9
 
 of exon 1; and a 0.4-kb EcoRI-
NcoI fragment 7 kb 5
 
9
 
 of exon 1 (probe 2).
 
Transgenic Mice.
 
The construct containing a 9-kb pT
 
a
 
 5
 
9
 
fragment upstream of LacZ and SV40 intron/Poly(A) sequences
in the p
 
b
 
gal-Basic vector was digested with XhoI/SalI and gel-
purified to remove the vector backbone. DNA was microinjected
into fertilized oocytes from FVB mice, and transgenic founders
were bred with wild-type FVB mice. A 0.25-kb AspI-PstI probe
from the 3
 
9
 
 end of the 9-kb pT
 
a
 
 fragment hybridized with 5-
and 1.6-kb EcoRV fragments from the endogenous pT
 
a
 
 gene
and the transgene, respectively, and was used for transgene copy
number determination by PhosphorImager (Molecular Dynam-
ics) quantitation. Total RNA was extracted from various organs
of 4-wk-old F1-transgenic mice, and Poly(A) RNA was prepared
from 250 
 
m
 
g total RNA using biotin-oligo(dT)/streptavidin
magnetic beads (Roche Molecular Biochemicals). Transgene ex-
pression was analyzed by Northern hybridization with a 5
 
9
 
 1.3-kb
fragment of LacZ gene.
 
RNase Protection Assay.
 
An NcoI fragment spanning 1.6 kb
5
 
9
 
 of the pT
 
a
 
 first exon was subcloned in the reverse orientation
into the NcoI site of pSL301 vector and linearized with EcoRV.
A 0.4-kb 
 
a
 
-[
 
32
 
P]dUTP–labeled riboprobe was synthesized using
T3 RNA polymerase and hybridized with 20 
 
m
 
g total RNA
from the indicated cell lines. After digestion with RNase T
 
1
 
 and
A, the protected fragments were resolved on a 6% denaturing se-
quencing gel in parallel with a DNA sequencing ladder as a
marker.
 
Transfections.
 
Cells were transferred into 6-well plates and
transfected with 1–2 
 
m
 
g DNA/well in duplicate, using lipid re-
agents according to the manufacturers’ instructions. Cell lines
LR1, BW5147, MEL, and NIH3T3 were transfected using Fu-
gene 6 reagent (Roche Molecular Biochemicals); cells from cell
lines LR2 and 642 were transfected using Superfect reagent
(Qiagen). LacZ reporter vectors containing no promoter (p
 
b
 
gal-
Basic) or SV40 promoter (p
 
b
 
gal-Promoter) were used as controls
in all experiments. After 24 h, cells were harvested and 
 
b
 
-galac-
tosidase activity was measured using a chemiluminescent assay
(Clontech or Tropix) in the scintillation counter. The results rep-
resent mean cpm 
 
6
 
 range of duplicate transfections. Note that
these are arbitrary units depending on the assay conditions; in
particular, the assay from Tropix was found to be 10–100 times
more sensitive than the assay from Clontech.
 
Electrophoretic Mobility Shift Assay.
 
For crude nuclear extract
preparation, cell nuclei were isolated by hypotonic lysis, and pro-
teins were extracted with a buffer containing 0.4 M NaCl. Each
binding reaction (15 
 
m
 
l) contained 10 fmol (10
 
5
 
 cpm) 
 
g
 
-[
 
32
 
P]
dATP–labeled double-stranded oligonucleotide probe, 3–5 
 
m
 
g nu-
clear protein extract, 0.5 
 
m
 
g poly(dI-dC), and, where indicated, a
100-fold excess of unlabeled oligonucleotide or 2 
 
m
 
g Ab. Binding
was performed for 20 min at room temperature in a final concen-
tration of 50 mM NaCl; 20 mM Tris/HCl, pH 7.5; 1 mM EDTA;
1 mM dithiothreitol; and 10% glycerol. Protein–DNA complexes
were separated on 4% nondenaturing polyacrylamide gels in 0.5
 
3
 
Tris/borate/EDTA buffer and visualized by autoradiography.
Oligonucleotide probes 1–6 spanning the core enhancer are de-
picted (see Fig. 6). Other probes included consensus oligonucle-
otides for YY1 (Santa Cruz Biotechnology), Sp1 (Promega Corp.),
and Ikaros (IK-BS2; reference 19), and an 
 
lck
 
 proximal promoter
 
2
 
365/
 
2
 
328 probe (lckB; reference 20). Anti-YY1 mAb and anti-
Sp1 and -Sp3 polyclonal Ab were purchased from Santa Cruz Bio-
technology. Anti-ZBP89 rabbit antiserum was provided by Drs.
Juanita Merchant and David Law (University of Michigan, Ann 
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Arbor, MI) and was used as protein A–purified IgG fraction. Puri-
fied anti-CD3 mAb 145-2C11 was used as a negative control.
Potential transcription factor binding sites were analyzed using
the TRANSFAC database and software (http://transfac.gbf.de;
reference 21).
 
Results
 
Specific DNase-hypersensitive Sites Upstream of the pT
 
a
 
 Gene.
 
Because regulatory genomic regions often display increased
sensitivity to DNase I treatment, we searched for such
DNase-hypersensitive sites (DHS) in the pT
 
a
 
 locus of T
cell lymphomas manifesting or lacking pT
 
a
 
 expression. We
first used a probe corresponding to pT
 
a
 
 exon 2 in conjunc-
tion with several restriction digests shown in Fig. 1 A. No
strong DHS correlating with pT
 
a
 
 expression were detected
within or downstream of the pT
 
a
 
 gene (EcoRV and NheI
digests in Fig. 1 B and data not shown). A nonspecific DHS
was detected 4 kb downstream of the last exon in all cell
lines tested, confirming the validity of the analysis (NheI di-
gest, Fig. 1 B). In contrast, a specific site (DHS 1) was found
immediately upstream of the first exon in pT
 
a
 
-positive but
not pT
 
a
 
-negative T cell lines (BamHI digest, Fig. 1 B).
To examine the regions further upstream of the pTa
gene, we initially used a probe detecting a 10-kb BglII
fragment 59 of the gene (data not shown). This preliminary
analysis suggested the presence of a specific DHS within
the region; however, a nonspecific DHS immediately 39 to
the probe precluded more precise mapping. To better lo-
calize the potential second DHS, we used a more down-
stream fragment as a probe (probe 2, Fig. 1 A). As shown in
Fig. 1 C, these experiments revealed the presence of two
closely located DHS, collectively referred to as DHS 2,
z4–4.5 kb upstream of the first pTa exon specifically in
pTa-positive cell lines. Thus, the genomic region 59 of
pTa harbors at least two specific DHS and is likely to play
a major role in the regulation of pTa expression.
The Region Upstream of pTa Can Drive Thymocyte-specific
Transgene Expression. To verify that putative regulatory
regions upstream of the pTa gene were sufficient for pre-T
cell–specific gene expression, we created transgenic mice
carrying the marker gene LacZ under the control of a pTa
59 fragment. The transgene contained 9 kb of pTa 59 re-
gion, including both DHS and a part of the known 59
UTR, upstream of LacZ and SV40 intron and Poly(A) sig-
nal. The heterozygous progeny of transgenic founders were
analyzed for transgene expression by Northern hybridiza-
tion with a LacZ probe.
Figure 1. DNase hypersensitivity analysis
of the mouse pTa locus. (A) Map of the pTa
gene showing restriction fragments and ge-
nomic probes used. The exons and UTR
(16) are shown as filled and empty boxes, re-
spectively. The approximate positions of
nonspecific (empty arrowheads) and specific
(filled arrowheads) DHS are indicated. In B,
genomic DNA from pTa-positive and -nega-
tive cell lines was treated with increasing
concentrations of DNase I, digested with in-
dicated enzymes, and hybridized with probe
1. The band corresponding to DHS 1 is indi-
cated (arrow). The positions of DNA size
markers (kb) are shown. In C, the same
DNA samples were digested with ScaI and
hybridized with probe 2. The bands corre-
sponding to DHS 2 are indicated (arrows).1672 Regulation of Pre-T Cell Receptor a Gene Expression
Of six transgenic lines analyzed, two lines manifested de-
tectable LacZ expression in the thymus. Both lines ex-
pressed LacZ in the thymus but not in the spleen; the line
carrying fewer copies of the transgene (four copies) was an-
alyzed in more detail. As shown in Fig. 2, the marker gene
was expressed exclusively in the thymus but not in the
spleen, lymph nodes, or other organs, with a pattern and
abundance comparable to that of the endogenous pTa
gene. Thus, a 9-kb 59 genomic fragment of the pTa gene
supported thymus-specific transgene expression in two
transgenic mouse lines. We therefore conclude that this
fragment contains all information necessary for pTa ex-
pression in thymocytes.
Characterization of a Proximal pTa Promoter. Because of
its position 59 of the first exon, the first DHS (DHS 1) was
likely to reflect the activity of a proximal promoter. To
confirm this notion, we analyzed the 59 transcriptional start
of the pTa gene by RNase protection assay, using a probe
spanning 0.4 kb immediately upstream of the translation
start site (Fig. 3 A). Fig. 3 B shows the presence in T cell
lymphomas of heterogeneous pTa transcripts initiated
within 100–200 bp of ATG, with the most abundant tran-
script corresponding to a short 59 UTR of z124 bp. This
Figure 2. Expression of a
LacZ marker gene driven by
pTa upstream fragment in trans-
genic mice. Poly(A) RNA from
the indicated organs of trans-
genic or wild-type (WT) litter-
mates was analyzed by Northern
hybridization with a LacZ probe,
and then the blot was stripped
and rehybridized with the pTa
cDNA probe and GAPDH
cDNA probe. The blot was ex-
posed for 4 h for LacZ and pTa
probes and 0.5 h for GAPDH
probe. The positions of 28S and
18S rRNA are indicated.
Figure 3. Characterization of the pTa proximal pro-
moter. (A) The sequence immediately upstream of the
translation start site (16). A putative transcription start site,
the 59 end of the longest cDNA clone (16), and the 39 end
of a riboprobe used for RNase protection are shown. The
PstI site represents the 39 end of the cloned pTa promoter
fragments. The PpuMI-PstI fragment corresponds to a
0.15-kb core pTa promoter. (B) RNase protection was
performed using RNA from the indicated cell lines and the
414-bp riboprobe shown above. The positions of a free
probe and of the sequencing ladder fragments (bp) corre-
sponding to the bands are indicated. A major protected
fragment corresponding to the putative transcription start
site is marked (arrow). (C) LacZ reporter constructs were
transiently transfected into LR1 or MEL cells, and b-galac-
tosidase activity was determined with a chemiluminescent
assay. The promoters included SV40 promoter, 1.2-kb
pTa promoter in direct or reverse (rev.) orientation, and
0.15-kb pTa promoter.1673 Reizis and Leder
position is only 5 bp 59 of the longest pTa cDNA clone
(16) and might represent a major transcription start site.
To examine the promoter function of the sequences ad-
jacent to the identified transcription start site, a 1.3-kb frag-
ment spanning this region was subcloned upstream of a
LacZ (b-galactosidase) reporter gene and transfected into
the T cell line LR1. This early passage cell line, derived
from an atm2/2rag-22/2 thymoma, has an immature T cell
phenotype (Thy-1hiCD4loCD8loCD2loCD252CD442TCR-
b2pTa1) and can be transfected using lipid reagents. As
shown in Fig. 3 C, the pTa upstream fragment manifested
a relatively weak orientation-dependent promoter activity.
Using 59 deletions of the fragment, the promoter function
was localized to a 0.15-kb PpuMI-PstI fragment containing
115 bp 59 of the putative transcription start site. Although
the low activity of pTa promoter precluded the analysis of
its function in other T cell lines, the promoter was inactive
in an erythroleukemia cell line, MEL (Fig. 3 C) and in
NIH3T3 fibroblasts (not shown). Thus, DHS 1 apparently
corresponds to a short proximal promoter that might be
specific at least for lymphoid cells.
Characterization of an Upstream pTa Enhancer. To search
for the possible distal enhancers in the pTa locus, we ex-
amined the effect of larger pTa genomic fragments in a
transient transfection assay with LR1 T cells. As shown in
Fig. 4, a 9-kb 59 pTa fragment, used in the transgene as
described above, was more active than a 0.5-kb 59 fragment
containing the core promoter. Using in-vector deletions of
the 9-kb region, we first localized the enhancer activity to a
2.8-kb XbaI fragment. By creating a series of nested 59 and
39 deletions of this fragment (data not shown), this activity
was further mapped to a 0.35-kb region between BstEII
and NarI sites, 4 kb upstream of the pTa promoter. Fig. 4
demonstrates that this fragment and a smaller 0.25-kb
BstEII-MluNI fragment were fully active as transcriptional
enhancers. In contrast, 59 or 39 truncations at a PstI site
within this region significantly reduced the enhancer func-
tion. Importantly, these mapping data are consistent with
the location of DHS 2, suggesting that the described pTa
enhancer is at least one regulatory region corresponding to
DHS 2.
Fig. 4 also demonstrates that pTa enhancer increased
transcription when placed in either orientation and at a
variable distance from the promoter. To examine its activ-
ity on heterologous promoters, the larger 4.3-kb and the
smaller 0.35-kb fragments containing the pTa enhancer
were subcloned upstream of the SV40 early promoter. As
shown in Fig. 5 A, both pTa enhancer fragments signifi-
cantly increased the activity of the SV40 promoter in LR1
T cells. The activity of pTa enhancer in LR1 cells was
stronger than that of previously described T cell–specific
enhancers of CD3d (Fig. 5 A) and CD2 (not shown) genes
and was also observed with another strong heterologous
promoter, the CMV immediate early promoter (data not
shown). Thus, the identified upstream enhancer of the pTa
gene appears as a powerful, bona fide transcriptional en-
hancer, functioning irrespective of distance, orientation, or
the corresponding promoter (22).
To examine the cell and stage specificity of the pTa en-
hancer, the enhancer/SV40 promoter constructs were in-
troduced into a pTa-negative T cell line, BW5147. As
shown in Fig. 5 A, the large enhancer fragment was com-
pletely inactive, whereas the small, 0.35-kb fragment pro-
duced only a minor increase similar to the CD3d enhancer.
Similar results were obtained with smaller enhancer frag-
ments (not shown). This was not due to a limiting transfec-
tion efficiency, as the CMV promoter produced a strong
reporter activity in these cells. A similarly low activity of
the pTa enhancer was observed in nonlymphoid MEL and
NIH3T3 cells (data not shown). In another series of exper-
iments, the same reporter constructs were introduced into
pTa-positive (642) or -negative (LR2) T cell lines. These
early passage T cell lymphomas could be transfected with a
comparable low efficiency by the same protocol. Fig. 5 B
demonstrates that the pTa enhancer increased the pro-
moter activity in 642 cells but was scarcely functional in
LR2 cells compared with the control CD3d enhancer. Al-
together, these data suggest, but do not prove, that the pTa
enhancer is preferentially active in pre-T cells as compared
with mature T cells or nonlymphoid cells.
Nuclear Factors Binding to the Core pTa Enhancer. The se-
quence of the 0.25-kb BstEII-MluNI enhancer fragment
Figure 4. Mapping of the pTa
upstream enhancer. The reporter
constructs were transiently trans-
fected into LR1 cells, and b-galac-
tosidase activity was determined 24 h
later. The indicated upstream ge-
nomic pTa fragments were sub-
cloned 59 of the pTa promoter frag-
ments (shown as arrows) in the LacZ
reporter vector. A 10-kb down-
stream pTa genomic fragment was
used as a control. The BstEII-NarI
fragment was used either in forward
or reverse orientation.1674 Regulation of Pre-T Cell Receptor a Gene Expression
was determined and is shown in Fig. 6 A. Nested 59 and 39
deletions of this region were produced by PCR using the
indicated primers, subcloned into the SV40 promoter/
LacZ reporter vector, and assessed for their activity in LR1
cells (Fig. 6 B). This analysis revealed a core enhancer of
149 bp, defined by primers F2 and R2. Further deletions in
this region significantly decreased the enhancer activity; the
regions between F2/F3, R2/R3, and R4/R5 appeared
particularly important. These data are consistent with the
deleterious effect of truncations at the PstI site within the
core enhancer region (Fig. 4).
Next, we examined nuclear proteins binding to the pTa
enhancer by electrophoretic mobility shift assay (EMSA)
using nuclear extracts from several pTa-positive or -nega-
tive T cell lines, a B cell line, and an erythroleukemia cell
line. As probes, we used six double-stranded oligonucle-
otides spanning the core enhancer (Fig. 6 A) or larger pro-
moter and enhancer DNA fragments. This analysis revealed
multiple distinct nuclear factors interacting with the core
enhancer; however, we were unable to detect any DNA–
protein complexes appearing specifically in pTa-expressing
T cell lines.
Figure 5. Activity of the pTa en-
hancer in various T cell lines. The
4.3- and 0.35-kb pTa enhancer
fragments and the control CD3d en-
hancer were subcloned upstream of
the SV40 promoter/LacZ reporter
gene. (A) The cells were transfected
using Fugene 6 reagent. A CMV
promoter/LacZ construct was used
as a positive control for transfection
of BW5147 cells. In B, the cells
were transfected using Superfect re-
agent.
Figure 6. Fine mapping of the
pTa enhancer. (A) Sequence of the
0.25-kb BstEII-MluNI enhancer
fragment, showing forward (F) and
reverse (R) primers used for amplifi-
cation of the deletion fragments.
The oligonucleotide probes 1–6
used for EMSA are underlined. The
PstI site and the mutation intro-
duced at the putative YY1 binding
site are indicated. The sequence is
available from EMBL/GenBank/
DDBJ under accession no.
AF132612. In B and C, the en-
hancer fragments were subcloned
upstream of the SV40 promoter/
LacZ reporter gene and assayed by
transient transfection of LR1 cells.
(B) Nested enhancer deletions were
amplified by PCR with the indi-
cated primer pairs. (C) The YY1 site
mutation shown above (YY1m) was
introduced into the 0.25-kb en-
hancer fragment by site-directed
mutagenesis.1675 Reizis and Leder
The core enhancer sequence contained a potential bind-
ing site (CCAT; reference 23) for the transcription factor
YY1. Indeed, probe 3, containing the putative YY1 site,
formed a complex, found in all cells examined, that could
be specifically competed by YY1 consensus oligonucle-
otide (Fig. 7). Furthermore, Fig. 7 shows that the factor
binding to both probes could be supershifted by anti-YY1
Ab, thus confirming its identity as YY1. To explore the
functional role of this interaction, the YY1 binding site was
mutated so that the mutant sequence was unable to com-
pete with YY1 binding (not shown). As shown in Fig. 6 C,
the YY1 site mutation resulted in a minor, but consistent,
increase in enhancer activity. Thus, the core pTa enhancer
appears to interact with YY1 transcription factor, which
might contribute to the repression of its activity.
C-rich Sites in the Core Enhancer Bind ZBP-89. It was
reported previously that the thymocyte-specific lck proxi-
mal promoter contains a G-rich site that appears critical for
the promoter function and binds a T cell nuclear factor
(factor B) (20). Because the pTa enhancer sequence fea-
tures two similar C-rich stretches, we examined the factors
binding to these sites and their possible relation to factor B
of the lck promoter. Enhancer probes 2, 5, and 6 produced
a similar pattern of nuclear complexes and effectively com-
peted with each other for binding (not shown); we there-
fore concluded that the 59 and 39 C-rich sites bind the same
nuclear factors. Fig. 8 demonstrates that enhancer probe 2,
encompassing the 59 C-rich site, formed two distinct com-
plexes in T cell nuclear extracts. The upper complex was
specifically competed out by an Sp1 consensus probe,
whereas the lower complex was competed out by the
G-rich B site of lck promoter (lckB); moreover, the labeled
lckB probe formed a single complex of similar size. Anti-
body supershift experiments confirmed that the upper
complex consisted of Sp1 and Sp3 transcription factors
(Fig. 8, center panel). Thus, the C-rich enhancer regions
bind Sp1 family proteins and another protein identical to
the B complex of lck promoter.
A recently cloned zinc finger transcription factor, ZBP-
89 (BFCOL1, BERF-1), was shown to bind long, G-rich
Figure 7. The pTa enhancer binds transcription factor YY1. EMSA
was performed with LR1 nuclear extract and labeled probe 3 from pTa
enhancer or YY1 consensus probe (YY1c). In the left panel, the reactions
included a 100-fold excess of unlabeled enhancer probes (Fig. 6) or YY1
consensus probe. In the right panel, anti-YY1 mAb or a control mAb
were added to the reactions.
Figure 8. The pTa enhancer
binds Sp family transcription fac-
tors and ZBP-89. EMSA was per-
formed with EL4 nuclear extract
and labeled enhancer probe 2 or
lckB probe. Cold competitor oli-
gonucleotides included enhancer
probe 2, lckB probe, Sp1 consen-
sus probe (Sp1c), or a control
Ikaros consensus probe (IKc). An-
tibodies to transcription factors
were added as shown. The com-
plexes containing Sp1/Sp3 or
ZBP-89 are indicated (arrows).1676 Regulation of Pre-T Cell Receptor a Gene Expression
stretches in several promoters (24–26) and, therefore, rep-
resented a good candidate for the observed binding activity.
We tested this possibility and found that anti–ZBP-89 Ab
specifically blocked the formation of the lower complex
with probe 2 and of the major complex with lckB probe
(Fig. 8, right panel). Thus, ZBP-89 appears to interact with
two sites within the pTa enhancer core and with a critical
site of the lck proximal promoter. These observations sug-
gest a possible role for ZBP-89 in thymocyte-specific gene
expression.
Discussion
This study was aimed at establishing a model to study the
regulation of pre-T cell–specific gene transcription. The reg-
ulation of genes expressed at the early stages of B cell devel-
opment has been extensively studied, and stage-specific tran-
scription factors such as EBF (early B cell factor) have been
identified (27). In contrast, the mechanisms of stage-specific
gene expression in T cells are less well understood. Certain
transcription factors appear to regulate specific stages of T
cell development, as illustrated by the role of LKLF (lung
Kruppel-like factor) in the maintenance of mature T cell
quiescence (28). A clear example of reciprocal transcriptional
regulation in early versus mature T cells is the alternative
promoter usage at the lck tyrosine kinase gene (5). In particu-
lar, the lck proximal promoter was proven to function specif-
ically in immature thymocytes (20) and has been extensively
used to target transgene expression to early T cells. In an-
other case, a thymocyte-specific enhancer was found in the
third intron of Thy-1 gene (29). Furthermore, stage-specific
silencers and enhancers were described in the CD4 (6, 7) and
CD8 (8–10) loci, respectively. Despite this progress, the mo-
lecular basis of an apparently common pattern of pre-T cell–
specific transcription is obscure.
The expression of the pTa gene has been examined in
great detail and was shown to occur specifically in pre-T cells
(13, 14). Recently, the expression of an alternatively spliced
pTa isoform (lacking the extracellular Ig domain) was de-
scribed (30, 31) and proposed to occur in mature T cells as
well as in pre-T cells (30). This isoform was also observed in
the original analysis of pTa expression but was not detected
in mature T cells (14). Similarly, we could not detect its
expression in the spleen or in pTa-negative T cell lines
(Reizis, B., unpublished results). Therefore, the expression
of a shorter pTa isoform in mature T cells is likely to occur,
if at all, only in a specialized minor population of T cells or at
extremely low levels. Thus, by and large, the pTa gene ap-
pears to be expressed in early T cells and as such represents a
valuable model for stage-specific T cell gene expression.
Although the mouse and human pTa genes have been
extensively mapped and sequenced (16, 31), the regulation
of pTa gene expression has not been studied. We now re-
port that mouse pTa gene transcription is regulated prima-
rily by an upstream genomic region. It is possible, how-
ever, that additional genomic elements within, downstream
of, or farther upstream of the gene might contribute to its
regulation. In particular, possible locus control regions con-
ferring position-independent transgene expression remain
to be identified in the pTa locus; the nonspecific DHS 59
and 39 of the gene are candidates for such elements. An-
other likely regulatory region is the recently described se-
quence in the first pTa intron, which is conserved between
mouse and human genes (31). We found that a fragment
containing this sequence lacked any detectable enhancer
activity in a transient transfection assay (data not shown);
thus, it might function as a silencer or an element regulat-
ing chromatin accessibility. Further studies are required to
delineate the complete hierarchy of pTa transcriptional
regulation. In any case, our data indicate that the cell and
stage specificity of pTa expression are fully determined by
upstream elements.
Within the pTa upstream region, we have identified a
proximal promoter and an enhancer located 4 kb 59 of the
promoter. As in many T cell–specific genes, the promoter
appeared relatively weak and is most likely insufficient for
pTa expression. The pTa enhancer, on the other hand,
manifested high activity in transient transfection assays and
appeared to function preferentially in pTa-positive pre-T
cell lines. It is possible, however, that additional elements
in the vicinity of the enhancer contribute to its specificity.
In this regard, it is noteworthy that DHS 2 actually consists
of two sites separated by z0.3–0.4 kb; the precise nature of
these sites is currently under investigation. In addition, the
enhancer may require its cognate pTa promoter to achieve
full specificity.
Our analysis of the nuclear factors interacting with the
core pTa enhancer (Figs. 7 and 8, and Reizis, B., unpub-
lished data) suggests a preliminary model of its architecture
(Fig. 9). We could detect at least two distinct factors bind-
ing to the 59 end of the sequence, and these interactions
appear important for the enhancer function, as evidenced
by the F2/F3 deletion (Fig. 6). The two 59 E boxes appear
to have formed identical complexes, whereas the 39 E box
represents a consensus binding site for bHLH-ZIP transcrip-
tion factors and might bind a distinct set of proteins. The en-
hancer features a perfect Ikaros binding site, and probe 4,
spanning this site, formed a nuclear complex that was specif-
ically inhibited by Ikaros consensus probe IK-BS2 (19) and
vice versa; however, we were unable to confirm the iden-
Figure 9. The proposed architecture of the pTa enhancer. Putative binding sites for nuclear factors are marked.1677 Reizis and Leder
tity of this factor using anti-Ikaros antiserum. Nevertheless,
Ikaros protein isoforms or Ikaros-related factors might in-
teract with this site in vivo and contribute to the repression
of the enhancer by recruiting it to centromeric heterochro-
matin in pTa-negative cells (32, 33). In addition, transcrip-
tion factor YY1 binds to the middle portion of the en-
hancer and appears to repress its activity. YY1 is a
multifunctional factor implicated in, among other things,
the repression of tissue-specific genes such as Ig and globin
genes, possibly due to the recruitment of corepressors such
as histone deacetylases (34). Thus, the pTa enhancer may
be subject to the complex regulation at the level of chro-
matin modification.
The pTa enhancer contains two C-rich sites, and dele-
tion of the 39 site compromised the enhancer function (Fig.
6). We found that these sites bind Sp1 and Sp3, the related
ubiquitous transcriptional activator and repressor proteins,
respectively (35). The true role of Sp proteins in the regu-
lation of the pTa enhancer might be difficult to establish;
indeed, the expression of many genes thought to be regu-
lated by Sp1 was not affected in its absence (35). It should
be noted, however, that Sp1 is abundantly expressed in the
thymus (36) and therefore might play a specific role in thy-
mocyte gene expression.
In addition, these C-rich sites, as well as an important
G-rich site in the proximal lck promoter, bind a common nu-
clear factor identified here as ZBP-89. The truncated clone
of ZBP-89, htb, was originally cloned as a zinc finger pro-
tein binding to the CACCC box in the human TCR-a
promoter (37). Recently, the full length protein ZBP-89/
BFCOL1/BERF-1 was cloned as a protein binding to
long, G-rich stretches in various promoters (24–26, 38,
39). This protein appears to be capable of both transcrip-
tional activation (25, 26, 37) and repression (24, 26, 38),
possibly depending on the DNA context and cell type; the
precise function of ZBP-89 on the pTa enhancer remains
to be established. Despite its apparently ubiquitous expres-
sion, we have found that ZBP-89 mRNA is expressed in
the thymus at significantly higher levels than in any other
organ tested, including the spleen (Reizis, B., unpublished
results). Indeed, six out of eight cDNA clones correspond-
ing to ZBP-89 in the mouse expressed sequence tag data-
base are derived from the thymus library. In addition, the
ZBP-89 complex was easily detectable by EMSA in T cell
lines but not in nonlymphoid cells such as MEL. Together
with the observed binding of ZBP-89 to the regulatory ele-
ments active specifically in early T cells, these observations
suggest an important role of ZBP-89 in T cell development.
A proposed model of the pTa core enhancer differs sig-
nificantly from the core enhancers of TCR genes (3); in
particular, it lacks obvious binding sites for T cell–specific
transcription factors such as GATA3 or TCF1/LEF1. Fur-
thermore, we were unable to detect enhancer-binding nu-
clear factors directly correlating with pTa expression in T
cell lines. This may be due to the technical limitations of
our approach, or it might reflect the requirement for addi-
tional regulatory sites as discussed above. Another possibil-
ity, however, is the existence of protein cofactors interact-
ing with the enhancer-binding proteins and conferring cell
and stage specificity on the enhancer. Indeed, the bHLH
proteins, YY1 and Sp1, are known to be involved in com-
plex interactions with other proteins, which are essential
for their function on a particular regulatory region. Simi-
larly, ZBP-89 is likely to undergo cell type–specific regula-
tion by other proteins. Future studies using this and other
models should delineate the precise mechanism of stage-
specific gene expression in T cells.
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